REDWOOD CITY, Calif., Oct. 10, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from eight Oncotype DX® Breast Recurrence Score™ (RS) presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, highlighting superior clinical evidence in identifying which patients with node-negative and node-positive invasive breast cancer should be treated with chemotherapy. Specifically, prospective clinical outcomes in more than 7,400 patients with node-positive invasive breast cancer from two independent studies show excellent survival in women with RS results less than 18.

"The ESMO presentations continue to reinforce that Oncotype DX provides unique and unsurpassed value beyond tumor size and tumor grade for invasive breast cancer patients with node-negative and certain patients with node-positive disease," said Steven Shak, M.D., chief scientific officer, Genomic Health. "With our level 1 evidence for predicting chemotherapy benefit and prospective outcomes now in over 63,000 patients from the TAILORx, Clalit, PlanB and SEER studies, it is clear that Oncotype DX is the only genomic test that can provide doctors with confidence that their patients will receive the quality care they deserve."

As the only genomic test proven to predict chemotherapy benefit, the Oncotype DX Breast Recurrence Score is included in all major cancer guidelines worldwide and now considered as standard of care for women with early-stage breast cancer.


As the only genomic test proven to predict chemotherapy benefit, the Oncotype DX Breast Recurrence Score is included in all major cancer guidelines worldwide and now considered as standard of care for women with early-stage breast cancer.

New data confirm Oncotype DX accurately predicts clinical outcomes in node-positive breast cancer patients

Two independent studies in more than 7,400 patients from the United States and Israel provide further evidence that Oncotype DX accurately predicts outcomes in patients with early-stage, node-positive invasive breast cancer. Specifically, an updated analysis of the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry results from 6,768 patients who were treated based on RS results showed that in 3,919 patients with a RS of less than 18, breast cancer specific survival was excellent. Specifically, it was greater than 97 percent in patients with micrometastases, one, or two positive lymph nodes.

Rad Oncology Homepage